Microbial efflux pump inhibition: Tactics and strategies

Current Pharmaceutical Design

Volumn 17, Issue 13, 2011, Pages 1291-1302

  Tegos, George P ^a,b,c,d   Haynes, Mark ^a   Strouse, J Jacob ^a   Khan, Mohiuddin Md T ^a   Bologa, Cristian G ^a,e   Oprea, Tudor I ^a,e   Sklar, Larry A ^a,b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Efflux pump substrates and inhibitors; High throughput screening; Multidrug resistance; Natural antimicrobials

Indexed keywords

ANTHRAQUINONE; ANTIINFECTIVE AGENT; BENZOIC ACID; BERBERINE; BIOCHANIN A; BIRICODAR; CHALCONE; CINNAMIC ACID; COUMARIC ACID; COUMESTROL; CRYSOPLENETIN; CRYSOPLENOL; EFFLUX PUMP INHIBITOR; ESCULETIN; GENISTEIN; GOSSYPOL; MULTIDRUG EFFLUX SYSTEM; MULTIDRUG RESISTANCE PROTEIN; NARINGENIN; NEOHESPERIDIN; OROBOL; PHEOPHORBIDE; PLUMBAGIN; PYRITHIONE; RESVERATROL; RHEIN; SALICYLIC ACID; STILBENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BIOASSAY; BIOFILM; DRUG ACTIVITY; DRUG STRUCTURE; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; MEMBRANE TRANSPORT; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; PURIFICATION;

EID: 79958177990     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795703726     Document Type: Article

References (184)

1. Poole K. Efflux-mediated antimicrobial resistance J. Antimicrob Chemother 2005; 56: 20-51.
2. Piddock L. Multidrug-resistance efflux pumps-not just for resistance. Nat Rev Microbiol 2006; 20: 629-36.
3. Piddock L. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19: 382-402.
4. Fletcher JI Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010; 10: 147-56.
5. Paulsen IT, Chen J, Nelson KE, Saier MHJ. Comparative genomics of microbial drug efflux systems In: Le wis K, ed., Microbial Multidrug Efflux. Horizon Press: Norfolk., 2002; pp. 5-21.
6. Ren Q, Paulsen IT. Comparative analyses of fundamental differences in membrane transport capabilities in prokaryotes and eukaryotes. PLoS Comput Biol 2005; 3: e27.
7. Cannon RD, Lamping E, Holmes AR, et al. Efflux-mediated antifungal drug resistance. Clin Microbiol Rev 2009; 2: 291-321.
8. Paumi CM, Chuk M, Snider J, Stagljar I, Michaelis S. ABC transporters in Saccharomyces cerevisiae and their interactors: new technology advances the biology of the ABCC (MRP) subfamily. Microbiol Mol Biol Rev 2009; 73: 577-93.
9. Coleman JJ, Mylonakis, E. Efflux in fungi: la pièce de résistance. PLoS Pathog 2009; 5: e1000486.
10. Lister P, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22: 582-610.
11. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000; 406: 959-64.
12. Yin Y, He X, Szewczyk P, Nguyen T, Chang G. Structure of the multidrug transporter EmrD from Escherichia coli. Science 2006; 312: 741-4.
13. Mirza O, Guan L, Verner G, Iwata S, Kaback HR. Structural Evidence for Induced Fit and a Mechanism for Sugar/H(+) Symport in LacY. EMBO J 2006; 25: 2038.
14. Huang Y, Lemieux MJ, Song J, Auer M, Wang DN. Structure and Mechanism of the Glycerol-3-Phosphate Transporter from Escherichia Coli. Science 2003; 301: 616-20.
15. Aller SG, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323: 1718-22.
16. Zawadzka A, Kim Y, Maltseva N, et al. Characterization of a Bacillus subtilis transporter for petrobactin, an anthrax stealth siderophore. Proc Natl Acad Sci USA 2009; 106: 21854-59.
17. Lemieux M. Eukaryotic major facilitator superfamily transporter modeling based on the prokaryotic GlpT crystal structure. Mol Membr Biol 2007; 24: 333-41.
18. Koronakis V, Sharff V, Koronakis E, Luisi B, Hughes C. Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature 2000; 405: 914-19.
19. Higgins MK, Bokma E, Koronakis E, Hughes C, Koronakis V. Structure of the periplasmic component of a bacterial drug efflux pump. Proc Natl Acad Sci USA 2004; 101: 9994-99.
20. Eswaran J, Koronakis E, Higgins MK, Hughes C, Koronakis V. Three's company: component structures bring a closer view of tripartite drug efflux pumps. Curr Opin Struct Biol 2004; 14: 741-47.
21. Sennhauser G, Bukowska MA, Briand C, Grütter MG. Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J Mol Biol 2009; 389: 134-45.
22. Phan G, Broutin I, Benabdelhak H, Benas P, Rety S, Picard M, et al. Detailed structural description of Pseudomonas aeruginosa OprM protein in non-symmetrical space groups and dynamical insights into the opening of the periplasmic gate. Structure 2010; 18: 507-17
23. Akama H, Matsuura T, Kashiwagi S, et al. Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa. J Biol Chem 2004; 279: 25939-42.
24. Federici L Du D, Walas F, et al. The crystal structure of the outer membrane protein VceC from the bacterial pathogen Vibrio cholerae at 1.8 A resolution. J Biol Chem 2005; 280:15307-14.
25. Long F, Su CC, Zimmermann MT, et al. Crystal structures of the CusA efflux pump suggest methionine-mediated metal transport. Nature 2010; 467: 484-8.
26. Symmons M, Bokma E, Koronakis E, Hughes C, Koronakis V Proc Natl Acad Sci USA 2009; 106: 7173-8.
27. Wilke MS, Heller M, Creagh AL, et al. The crystal structure of MexR from Pseudomonas aeruginosa in complex with its antirepressor ArmR. Proc Natl Acad Sci USA 2008; 105: 14832-7.
28. Alguel Y, Lu D, Quade N, Sauter S, Zhang X. Crystal structure of MexZ, a key repressor responsible for antibiotic resistance in Pseudomonas aeruginosa. J Struct Biol 2010; 172: 305-10.
29. Alguel Y, Meng C, Terán W, et al. Crystal structures of multidrug binding protein TtgR in complex with antibiotics and plant antimicrobials. J Mol Biol 2007; 369: 829-40.
30. Daniels C, Daddaoua A, Lu D, Zhang X, Ramos JL. Domain crosstalk during effector binding to the multidrug binding TTGR regulator. J Biol Chem 2010; 285: 21372-81.
31. Di Fiore A, Fiorentino G, Vitale RM, et al. Structural analysis of BldR from Sulfolobus solfataricus provides insights into the molecular basis of transcriptional activation in archaea by MarR family proteins. J Mol Biol 2009; 388: 559-69.
32. Hernández A, Maté MJ, Sánchez-Díaz PC, Romero A, Rojo F, Martínez JL. Structural and functional analysis of SmeT, the repressor of the Stenotrophomonas maltophilia multidrug efflux pump SmeDEF. J Biol Chem 2009; 284: 14428-38.
33. Yum S, Xu Y, Piao S, et al. Crystal structure of the periplasmic component of a tripartite macrolide-specific efflux pump. J Mol Biol 2009; 387:1286-97.
34. He X, Szewczyk P, Karyakin A, et al. Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 2010; 467: 991-4.
35. Lewis K. In search of natural substrates and inhibitors of MDR pumps. J Mol Microbiol Biotechnol 2001; 2: 247-54.
36. Chung YJ, Saier, MH Jr. SMR-type multidrug resistance pumps Curr Opin Drug Discov Devel 2001; 4:237-45.
37. Chung YJ, Krueger C, Metzgar D, Saier MH Jr. Size comparisons among integral membrane transport protein homologues in bacteria, Archaea, and Eucarya J Bacteriol 2001; 183: 1012-21.
38. Mitchell B, Brown M, Skurray RA. QacA multidrug efflux pump from Staphylococcus aureus: comparative analysis of resistance to diamidines, biguanidines, and guanylhydrazones. Antimicrob Agents Chemother 1998; 42: 475-7.
39. Kaatz GW, Seo SM, O'Brien, L, Wahiduzzaman M, Foster TJ. Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44: 1404-6.
40. Huet AA, Raygada J, Mendiratta K, Seo SM, Kaatz GW. Multidrug efflux pump overexpression in Staphylococcus aureus after single and multiple in vitro exposures to biocides and dyes. Microbiology 2008; 154: 3144-53.
41. DeMarco CE, Cushing L, Frempong-Manso E, Seo SM, Jaravaza TA, Kaatz GW Efflux-related resistance to norfloxacin, dyes, and biocides in bloodstream isolates of Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 3235-9.
42. Van Bambeke F, Balzi E, Tulkens, PM. Antibiotic efflux pumps Biochem Pharmacol 2000; 60: 457-70.
43. Vazquez-Laslop N, Zheleznova EE, Markham PN, Brennan RG, Neyfakh AA. Recognition of multiple drugs by a single protein: a trivial solution of an old paradox. Biochem Soc Trans 2000; 28: 517-20.
44. Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P. AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrob Agents Chemother 2008; 52: 557-62.
45. Elkins C, Nikaido H. Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominantly by two large periplasmic loops. J Bacteriol 2002; 184: 6490-8.
46. Mao W, Warren M, Black DS, et al. On the mechanism of substrate specificity by resistance nodulation division (RND)-type multidrug resistance pumps: the large periplasmic loops of MexD from Pseudomonas aeruginosa are involved in substrate recognition. Mol Microbiol 2002; 46: 889-901.
47. Santiviago C., Fuentes JA, Bueno SM, et al. The Salmonella enterica sv. Typhimurium smvA, yddG and ompD (porin) genes are required for the efficient efflux of methyl viologen. Mol Microbiol 2002; 46: 687-97.
48. Elkins C, Mullis LB. Mammalian steroid hormones are substrates for the major RND-and MFS-type tripartite multidrug efflux pumps of Escherichia coli. J Bacteriol 2006; 188: 1191-5.
49. Rajamohan G, Srinivasan VB, Gebreyes WA. Novel role of Acinetobacter baumannii RND efflux transporters in mediating decreased susceptibility to biocides. J Antimicrob Chemother 2010; 65: 228-32.
50. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003; 22:188-99.
51. Tekaia F, Latgé JP. Aminoglycosides are captured from both periplasm and cytoplasm by the AcrD multidrug efflux transporter of Escherichia coli. Curr Opin Microbiol 2005; 8: 385-92.
52. Aires J, Nikaido H. Aminoglycosides are captured from both periplasm and cytoplasm by the AcrD multidrug efflux transporter of Escherichia coli. J Bacteriol 2005; 187: 1923-9.
53. Gonzalez-Pasayo R, Martinez-Romero E. Multiresistance genes of Rhizobium etli CFN42. Mol Plant Microbe Interact 2000; 13: 572-7.
54. Palumbo J, Kado CI, Phillips DA. An isoflavonoid-inducible efflux pump in Agrobacterium tumefaciens is involved in competitive colonization of roots. J Bacteriol 1998; 180: 3107-13.
55. Tegos G, Stermitz FR, Lomovskaya O, Lewis K. Multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. Antimicrob Agents Chemother 2002; 46: 3133-41.
56. Agarwal S, Singh SS, Verma S, Kumar S. Antifungal activity of anthraquinone derivatives from Rheum emodi. J Ethnopharmacol 2000; 72: 43-6.
57. Didry N, Dubreuil L, Pinkas M. Activity of anthraquinonic and naphthoquinonic compounds on oral bacteria. Pharmazie 1994; 49: 681-3.
58. Barabote R, Johnson OL, Zetina E, San Francisco SK, Fralick JA, San Francisco MJ. Erwinia chrysanthemi tolC is involved in resistance to antimicrobial plant chemicals and is essential for phytopathogenesis. J Bacteriol 2003; 185: 5772-8.
59. Ravirala R, Barabote RD, Wheeler DM, et al. Efflux pump gene expression in Erwinia chrysanthemi is induced by exposure to phenolic acids. Mol Plant Microbe Interact 2007; 20: 313-20.
60. Brown D, Swanson JK, Allen C. Two host-induced Ralstonia solanacearum genes, acrA and dinF, encode multidrug efflux pumps and contribute to bacterial wilt virulence. Appl Environ Microbiol 2007; 73: 2777-86.
61. Lomovskaya O, Warren MS, Lee A, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45: 105-16.
62. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 2001; 3: 225-36.
63. Wang EJ, Casciano CN, Clement RP, Johnson WW. Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun 2001; 289: 580-5.
64. Aeschlimann J, Dresser LD, Kaatz GW, Rybak MJ. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:335-40.
65. Beck W, Cirtain M, Glover C, Felsted R, Safa A. Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Com 1988; 153: 959-66.
66. Mullin S, Mani N, Grossman TH. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). Antimicrob Agents Chemother 2004; 48: 4171-6.
67. Germann U, Shlyakhter D, Mason VS, et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anti-Cancer Drugs 1997; 8: 125-40.
68. Amaral L, Martins M, Viveiros M. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother 2007; 59: 1237-46.
69. Poelarends G, Mazurkiewicz P, Konings WN. Multidrug transporters and antibiotic resistance in Lactococcus lactis. Biochim Biophys Acta 2002; 1555: 1-7.
70. Markham P, Westhaus E, Klyachko K, Johnson ME, Neyfakh AA. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 2404-8.
71. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 2000; 97: 1433-7.
72. Tegos GP. Substrates and Inhibitors of microbial efflux pumps; Redifine the Role of Plant Antimicrobilas In: Rai M, Carpinella CM, Eds. Naturally occurring bioactive compounds: a new and safe alternative for control of pests and microbial diseases, Cambridge University Press Cambridge UK 2006; pp. 45-59
73. Stermitz FR, Beeson TD, Mueller PJ, Hsiang J, Lewis K. Staphylococcus aureus MDR efflux pump inhibitors from a Berberis and a Mahonia (sensu strictu) species. Biochem Syst Ecol 2001; 29: 793-8.
74. Stermitz FR, Tawara-Matsuda J, Lorenz P, Mueller P, Zenewicz L, Lewis K. 5-0-Methoxyhydnocarpin-D and pheophorbide A: Berberis species components that potentiate berberine growth inhibition of resistant Staphylococcus aureus. J Nat Prod 2000; 63: 1146-9.
75. Stermitz F Scriven LN. Tegos G, Lewis K Two flavonols from Artemisa annua which potentiate the activity of berberine and norfloxacin against a resistant strain of Staphylococcus aureus. Planta Med 2002; 68: 1140-1.
76. Stermitz FR, Halligan KM, Morel C, Tegos GP, Lewis K. Polyacylated neohesperidosides From Geranium caespitosum: bacterial multidrug resistance pump inhibitors. Bioorg Med Chem Lett 2003; 13: 1915-8.
77. Belofsky G, Percivil D, Lewis K, Tegos G, Ekart J. Phenolic Metabolites of Dalea versicolor that Enhance Antibiotic Activity Against Multi-Drug Resistant Bacteria. J Nat Prod 2004; 67: 481-4.
78. Belofsky G, Carreno R, Lewis K, Ball A, Casadei G, Tegos GP. Metabolites of the "smoke tree", Dalea spinosa, potentiate antibiotic activity against multidrug-resistant Staphylococcus aureus. J Nat Prod 2006; 69: 261-4.
79. Morel C, Stermitz FR, Tegos G, Lewis K. Isoflavones as potentiators of antibacterial activity. J Agric Food Chem 2003; 51: 5677-9.
80. Gibbons S, Moser E, Kaatz GW. Catechin gallates inhibit multidrug resistance (MDR) in Staphylococcus aureus. Planta Med 2004; 70: 1240-2.
81. Chérigo L, Pereda-Miranda R, Fragoso-Serrano M, Jacobo-Herrera N, Kaatz GW, Gibbons S. Inhibitors of bacterial multidrug efflux pumps from the resin glycosides of Ipomoea murucoides. J Nat Prod 2008; 71: 1037-45.
82. Pereda-Miranda R, Kaatz GW, Gibbons S. Polyacylated oligosaccharides from medicinal Mexican morning glory species as antibacterials and inhibitors of multidrug resistance in Staphylococcus aureus. J Nat Prod 2006; 69: 406-9.
83. Michalet S, Cartier G, David B, et al. N-caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. Bioorg Med Chem Lett 2007; 17: 1755-8.
84. Thota N, Koul S, Reddy MV, et al. Citral derived amides as potent bacterial NorA efflux pump inhibitors. Bioorg Med Chem 2008; 16: 6535-43.
85. Falcão-Silva V, Silva DA, Souza Mde F, Siqueira-Junior JP. Modulation of drug resistance in Staphylococcus aureus by a kaempferol glycoside from Herissantia tiubae (Malvaceae). Phytother Res 2009; 10: 1367-70.
86. Mohtar M, Johari SA, Li AR, et al. Inhibitory and resistancemodifying potential of plant-based alkaloids against methicillinresistant Staphylococcus aureus (MRSA). Curr Microbiol 2009; 59:181-6.
87. Lechner D, Gibbons S, Bucar F. Plant phenolic compounds as ethidium bromide efflux inhibitors in Mycobacterium smegmatis. J Antimicrob Chemother 2007; 62: 345-8.
88. Wei P, Kaatz GW, Kerns RJ. Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps. Bioorg Med Chem Lett 2004; 14: 3093-7.
89. Sangwan P, Koul JL, Koul S, et al. Piperine analogs as potent Staphylococcus aureus NorA efflux pump inhibitors. Bioorg Med Chem 2008; 16: 9847-57.
90. German N, Wei P, Kaatz GW, Kerns RJ. Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. Eur J Med Chem 2008; 43: 2453-63.
91. Sabatini S, Kaatz GW, Rossolini GM, Brandini D, Fravolini A. >From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump. J Med Chem 2008; 51: 4321-30.
92. Rodrigues L, Wagner D, Viveiros M, et al. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J Antimicrob Chemother 2008; 61: 1076-82.
93. Ball A. Casadei G, Samosorn S, et al. Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial. ACS Chem Biol 2006; 1: 594-600.
94. Samosorn S, Tanwirat B, Muhamad N, et al. Antibacterial activity of berberine-NorA pump inhibitor hybrids with a methylene ether linking group. Bioorg Med Chem 2009; 17: 3866-72.
95. Tomkiewicz D, Casadei G, Larkins-Ford J, et al. Berberine-INF55 (5-nitro-2-phenylindole) hybrid antimicrobials: effects of varying the relative orientation of the berberine and INF55 components. Antimicrob Agents Chemother 2010; 54: 3219-24.
96. Dolmans D, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3: 380-7.
97. Bressler N, Bressler SB. Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences. Investig Ophthalmol Vis Sci 2000; 41: 624-8.
98. Hamblin M, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci 2004; 3: 436-50.
99. Bhatti M, MacRobert A, Meghji S, Henderson B, Wilson MA. Study of the uptake of toluidine blue O by Porphyromonas gingivalis and the mechanism of lethal photosensitization. Photochem Photobiol 1998; 68: 370-6.
100. Wainwright M. Photodynamic antimicrobial chemotherapy (PACT) J Antimicrob Chemother 1998; 42: 13-28.
101. Tegos G, Hamblin MR. Phenothiazinium antimicrobial photosensitizers are substrates of bacterial multidrug resistance pumps. Antimicrob Agents Chemother 2006; 50: 196-203.
102. Tegos G, Masago K, Aziz F, Higginbotham A, Stermitz FR, Hamblin MR Inhibitors of bacterial multidrug efflux pumps potentiate antimicrobial photoinactivation. Antimicrob Agents Chemother 2008; 52: 3202-9.
103. Robey R, Fetsch PA, Polgar O, Dean M, Bates SE. The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2. Res Vet Sci 2006; 81: 345-9.
104. Robey R, Steadman K, Polgar O, Bates SE. ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy. Cancer Biol Ther 2005; 4: 187-94.
105. Grinholc M, Zawacka-Pankau J, Gwizdek-Wiśniewska A, Bielawski KP. Evaluation of the role of the pharmacological inhibition of Staphylococcus aureus multidrug resistance pumps and the variable levels of the uptake of the sensitizer in the straindependent response of Staphylococcus aureus to PPArg(2)-based photodynamic inactivation. Photochem Photobiol 2010; 86:1118-26
106. Wilson M, Yianni C. Killing of methicillin-resistant Staphylococcus aureus by low-power laser light. J Med Microbiol 1995; 42: 62-6.
107. Soncin M, Fabris C, Busetti A, et al. Approaches to selectivity in the Zn(II)-phthalocyanine-photosensitized inactivation of wild-type and antibiotic-resistant Staphylococcus aureus. Photochem Photobiol Sci 2002; 1: 815-9.
108. Bornstein E, Gridley S, Wengender P, Robbins A. Photodamage to multidrug-resistant gram-positive and gram-negative bacteria by 870 nm/930 nm light potentiates erythromycin, tetracycline and ciprofloxacin. Photochem Photobiol 2010; 86: 617-27.
109. Barrett J. MC-207110 Daiichi Seiyaku/Microcide Pharmaceuticals. Curr Opin Investig Drugs 2001; 2: 212-5.
110. Zechini B, Versace I. Inhibitors of Multidrug Resistant Efflux Systems in Bacteria. Recent Patents on Anti-Infective Drug Discovery 2009; 4: 37-50.
111. Nakayama K., Ishida Y, Ohtsuka M, et al. MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization. Bioorg Med Chem Lett 2003;13: 4201-4.
112. Nakayama K., Ishida Y, Ohtsuka M, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds Bioorg Med Chem Lett 2003; 13: 4205-8
113. Nakayama K., Kawato H, Watanabe J, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 3: Optimization of potency in the pyridopyrimidine series through the application of a pharmacophore model. Bioorg Med Chem Lett 2004; 14: 475-9.
114. Yoshida K., Nakayama K, Ohtsuka M, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg Med Chem Lett 2007; 15: 7087-97.
115. Nakayama K., Kuru N, Ohtsuka M, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 4: Addressing the problem of poor stability due to photoisomerization of an acrylic acid moiety. Bioorg Med Chem Lett 2004; 14: 2493-7.
116. Renau T, Léger R, Filonova L, et al. Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett, 2003; 13: 2755-8.
117. Yoshida K., Nakayama K, Yokomizo Y, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents. Bioorg Med Chem 2006; 14: 8506-18.
118. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic-A vision for applied use. Biochem Pharmacol 2006; 71: 910-18.
119. Pagès J, Masi M, Barbe J. Inhibitors of efflux pumps in Gram negative bacteria Trends Mol Med 2005; 11: 382-9.
120. Mahamoud A, Chevalier J, Libert-Franco S, Kern WV, Pages JM. Antibiotic efflux pumps in Gram negative bacteria: the inhibitory response strategy. J Antimicrob Chemother 2007; 59: 1223-9.
121. Mallèa M, Chevalier J, Eyraud A, Pagès JM. Inhibitors of antibiotic efflux pumps in resistant Enterobacter aerogenes strains. Biochem Biophys Res Commun 2002; 293: 1370-3.
122. Mazzariol A, Tokue Y, Kanegawa TM, Cornaglia G, Nikaido H. High level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein. Antimicrob Agents Chemother 2000; 44: 3441-3.
123. Hasdemir U, Chevalier J, Nordmann P, Pages JM. Detection and prevalence of active drug efflux mechanism in various multidrugresistant Klebsiella pneumoniae strains from Turkey. J Clin Microbiol 2004; 42: 2701-6.
124. Baucheron S, Imberechts H, Chaslus-Dancla E, Cloeckaert A. The AcrB multidrug transporters plasy a major role in high-level fluorquinolone resistance in Salmonella enterica serovar thyphimurium phage typer DT 204. Microb Drug Resist 2002; 8: 281-9.
125. Pannek S., Higgins PG, Steinke P, et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-betanaphthylamide. J Antimicrob Chemother 2006; 57: 970-4.
126. Hannula M, Hänninen ML. Effect of putative efflux pump inhibitors and inducers on the antimicrobial susceptibility of Campylobacter jejuni and Campylobacter coli. J Med Microbiol 2008; 57: 851-5.
127. Lin J, Martinez A. Effect of efflux pump inhibitors on bile resistance and in vivo colonization of Campylobacter jejuni. J Antimicrob Chemother 2006; 58: 966-72.
128. Thorarensen A, Presley-Bodnar AL, Marotti KR, et al. 3-Arylpiperidines as potentiators of existing antibacterial agents. Bioorg Med Chem Lett 2002; 11: 1903-6.
129. Kern W, Steinke P, Schumacher A, Schuster S, von Baum H, Bohnert JA. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 2006; 57: 339-43.
130. Coban A, Tanriverdi, Cayci Y, Erturan Z, Durupinar B. Effects of efflux pump inhibitors phenyl-arginine-beta-naphthylamide and 1-(1-naphthylmethyl)-piperazine on the antimicrobial susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Chemother 2009; 21: 592-4.
131. Piddock L, Garvey MI, Rahman MM, Gibbons S. Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria. J Antimicrob Chemother 2010; 65: 1215-23.
132. Tang J, Wang H. Indole derivatives as efflux pump inhibitors for TolC protein in a clinical drug-resistant Escherichia coli isolated from a pig farm. Int J Antimicrob Agents 2006; 5: 497-8.
133. Chan Y, Ong YM, Chua KL. Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei. Antimicrob Agents Chemother 2007; 51: 623-30.
134. Mahamoud A, Chevalier J, Davin-Regli A, Barbe J, Pagès JM. Quinoline derivatives as promising inhibitors of antibiotic efflux pump in multidrug resistant Enterobacter aerogenes isolates. Curr Drug Targets 2006; 7: 843-7.
135. Chevalier J, Bredin J, Mahamoud A, Malléa M, Barbe J, Pagès JM. Inhibitors of antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrob Agents Chemother 2004; 48: 1043-6.
136. Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol 2010; 16: 1279-84.
137. Maesaki S, Marichal P, Hossain MA, Sanglard D, Vanden Bossche H, Kohno S. Synergic effects of tactolimus and azole antifungal agents against azole-resistant Candida albican strains. J Antimicrob Chemother 1996; 42: 747-53.
138. Kolaczkowski M, Kolaczkowska A, Motohashi N, Michalak K. New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters. Antimicrob Agents Chemother 2009; 54: 1516-27.
139. Schuetzer-Muehlbauer M, Willinger B, Egner R, Ecker G, Kuchler K. Reversal of antifungal resistance mediated by ABC efflux pumps from Candida albicans functionally expressed in yeast. Int J Antimicrob Agents 2003; 3: 291-300.
140. Yamamoto S, Hiraga K, Abiko A, Hamanaka N, Oda K. A new function of isonitrile as an inhibitor of the Pdr5p multidrug ABC transporter in Saccharomyces cerevisiae. Biochem Biophys Res Commun 2005; 330: 622-8.
141. Niimi K, Harding DR, Parshot R, et al. Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother 2004; 48: 1256-71.
142. Lemoine R, Glinka TW, Watkins WJ, et al. Quinazolinone-based fungal efflux pump inhibitors. Part 1: Discovery of an (Nmethylpiperazine)-containing derivative with activity in clinically relevant Candida spp. Bioorg Med Chem Lett 2004; 14: 5127-31.
143. Watkins WJ, Lemoine RC, Chong L, et al. Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivatives. Bioorg Med Chem Lett 2004; 14: 5133-7.
144. Watkins W, Chong L, Cho A, et al. Quinazolinone fungal efflux pump inhibitors. Part 3: (N-methyl)piperazine variants and pharmacokinetic optimization. Bioorg Med Chem Lett 2007; 17: 2802-6.
145. Tanabe K, Lamping E, Adachi K, et al. Inhibition of fungal ABC transporters by unnarmicin A and unnarmicin C, novel cyclic peptides from marine bacterium. Biochem Biophys Res Commun 2007; 364: 990-5.
146. Digirolamo J, Li XC, Jacob MR, Clark AM, Ferreira D. Reversal of fluconazole resistance by sulfated sterols from the marine sponge Topsentia sp. J Nat Prod 2009; 72: 1524-8.
147. Singh P, Kaur J, Yadav B, Komath SS. Targeting efflux pumps-In vitro investigations with acridone derivatives and identification of a lead molecule for MDR modulation. Bioorg Med Chem 2010; 18: 4212-3.
148. Pina-Vaz C, Rodrigues AG, Costa-de-Oliveira S, Ricardo E, Mårdh PA. Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry. J Antimicrob Chemother 2005; 56: 678-85.
149. Pamp S, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008; 68: 223-40.
150. Zhang L, Mah TF. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics J Bacteriol 2008; 190: 4447-52.
151. Mukherjee P, Chandra J, Kuhn DM, Ghannoum MA. Mechanism of fluconazole resistance in Candida albicans biofilms: phasespecific role of efflux pumps and membrane sterols. Infect Immun 2003; 71: 4333-40.
152. Ramage G, Bachmann S, Patterson TF, Wickes BL, López-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms J Antimicrob Chemother 2002; 49: 973-80.
153. Imuta N, Nishi J, Tokuda K, Fujiyama R, Manago K, Iwashita, et al. Infect Immun 2008; 76: 1247-56.
154. Lynch S, Dixon L, Benoit M, Brodie E, Keyhan M, Hu P, et al. The Escherichia coli efflux pump TolC promotes aggregation of enteroaggregative E. coli 042 Antimicrob. Agents Chemother 2007; 51: 3650-8.
155. Rosenberg E, Bertenthal D, Nilles ML, Bertrand KP, Nikaido H. Bile salts and fatty acids induce the expression of Escherichia coli AcrAB multidrug efflux pump through their interaction with Rob regulatory protein. Mol Microbiol 2003; 48: 1609-19.
156. Gillis R, White K, Choi K, Wagner V, Schweizer H, Iglewski B. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2005; 49: 3858-67.
157. De Kievit T, Parkins M, Gillis R, Srikumar R, Ceri H, Poole K, et al. Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2001; 45: 1761-70.
158. O'Toole G, Stewart P. Biofilms strike back Nat Biotechnol 2005; 23: 1378-9.
159. Mah T, Pitts B, Pellock B, Walker GC, Stewart PS, O'Toole GA. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426: 306-10.
160. Kvist M, Hancock V, Klemm P. Inactivation of efflux pumps abolishes bacterial biofilm formation. Appl Environ Microbiol 2008; 74: 7376-82.
161. Kishen A, Upadya M, Tegos GP, Hamblin MR. Efflux pump inhibitor potentiates antimicrobial photodynamic inactivation of Enterococcus faecalis biofilm. Photochem Photobiol, 2010; 86: 1343-9.
162. Klyachko K, Schuldiner S, Neyfakh AA. Mutations affecting substrate specificity of the Bacillus subtilis multidrug transporter BMR J Bacteriol 1997; 179: 2189-93.
163. Ahmed M, Borsch C, Neyfakh A, Schuldner S. Mutants of Bacillus subtilis multidrug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine. J Biol Chem 1993; 268:11086-9.
164. Garvey M, Piddock LJ. The efflux pump inhibitor reserpine selects multidrug-resistant Streptococcus pneumoniae strains that overexpress the ABC transporters PatA and PatB Antimicrob Agents Chemother 2008; 52: 1677-85.
165. Gibbons S. Phytochemicals for bacterial resistance--strengths, weaknesses and opportunities Planta Med 2008; 74: 594-602.
166. Ji H, Li XJ, Zhang HY. Natural products and drug discovery EMBO reports 2009; 10: 194-200.
167. Demain A, Sanchez S. Microbial drug discovery: 80 years of progress. J Antibiot (Tokyo), 2009; 62: 5-16.
168. Lewis K, Ausubel FM Prospects for plant-derived antibacterials. Nat Biotechnol 2006; 24: 1504-7.
169. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 2008; 6: 17-27.
170. Winter S, Lovato DM, Khawaja HM, Edwards BS, Steele ID, Young SM, et al. High-throughput screening for daunorubicinmediated drug resistance identifies mometasone furoate as a novel ABCB1-reversal agent. J Biomol Screen 2008; 13: 185-93.
171. Johnson R, Allen C, Melman SD, et al. Identification of inhibitors of vacuolar proton-translocating ATPase pumps in yeast by highthroughput screening flow cytometry. Anal Biochem 2010; 398: 203-11.
172. Ivnitski-Steele I, Larson RS, Lovato DM, et al. High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters. Assay Drug Dev Technol 2008; 2: 263-76.
173. Ivnitski-Steele I, Holmes AR, Lamping E, Monk BC, Cannon RD, Sklar LA. Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Anal Biochem 2009; 394: 87-91.
174. The International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-36
175. Villarán R, Tomás-Camardiel M, de Pablos RM, et al. Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production J Neurotoxicology 2008; 2: 244-58.
176. Gandhi L, Harding MW, Neubauer M, et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer Cancer 2007; 109: 924-32.
177. Pusztai L., Wagner P, Ibrahim N, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapyresistant, advanced breast carcinoma Cancer 2005; 104: 682-91.
178. Bailey A, Paulsen IT, Piddock LJ. RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine. Antimicrob Agents Chemother 2008; 10: 3604-11.
179. Marquez B. Bacterial efflux systems and efflux pumps inhibitors Biochimie 2005; 87: 1137-47.
180. Couto I, Costa SS, Viveiros M, Martins M, Amaral L. Effluxmediated response of Staphylococcus aureus exposed to ethidium bromide J Antimicrob Chemother, 2008; 62: 504-13.
181. Ryder N. Antifungal agents IDrugs, 1999; 12: 1253-5.
182. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res 1981; 41: 1967-72.
183. Tonshin A, Teplova VV, Andersson MA, Salkinoja-Salonen MS. The Fusarium mycotoxins enniatins and beauvericin cause mitochondrial dysfunction by affecting the mitochondrial volume regulation, oxidative phosphorylation and ion homeostasis Toxicology 2010; 276: 49-57.
184. Lee M, Galazzo JL, Staley AL, et al. Microbial fermentationderived inhibitors of efflux-pump-mediated drug resistance Farmaco 2001; 56: 81-5.